FDA actions in brief
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Oxcarbazepine (Trileptal, Novartis) was approved as adjunctive therapy to treat partial seizures in children aged 2 years or older with epilepsy.
Abatacept (Orencia, Bristol-Myers Squibb) was approved to reduce the signs and symptoms of moderately to severely active rheumatoid arthritis in adult patients who have had an inadequate response to 1 or more disease-modifying antirheumatic drugs (DMARDs).
FDA approved divalproex extended-release tablets (Depakote ER, Abbott) for the treatment of acute manic or mixed episodes associated with bipolar disorder, with or without psychotic features.
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
